Private Capital’s LGND Holdings & Trades

First Buy
Q2 2024
Duration Held
6 Quarters
Largest Add
Q2 2024
+134,505 shares
Current Position
227,158 shares
$40.24 M value

Private Capital's LGND Position Overview

Private Capital (via Private Capital Management, LLC) currently holds 227.2K shares of Ligand Pharmaceuticals Incorporated (LGND) worth $40.24 M, representing 3.59% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 6 quarters.

Based on 13F filings, Private Capital has maintained this position in LGND for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 81.1K shares. Largest reduction occurred in Q3 2025, reducing 2.1K shares.

Analysis based on 13F filings available since 2013 Q2

Private Capital's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time

Track share changes against reported price movement

Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Private Capital

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2024 +134,505 New Buy 134,505 $84.26
Q3 2024 -625 Reduce 0.46% 133,880 $100.09
Q4 2024 -190 Reduce 0.14% 133,690 $107.15
Q1 2025 +14,435 Add 10.80% 148,125 $104.93
Q2 2025 +81,128 Add 54.77% 229,253 $113.68
Q3 2025 -2,095 Reduce 0.91% 227,158 $177.14

Private Capital's Ligand Pharmaceuticals Incorporated Investment FAQs

Private Capital first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q2 2024, acquiring 134,505 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Private Capital has held Ligand Pharmaceuticals Incorporated (LGND) for 6 quarters since Q2 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Private Capital's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q2 2024, adding 134,505 shares worth $11.33 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Private Capital's firm, Private Capital Management, LLC, owns 227,158 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $40.24 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 3.59% of Private Capital's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Private Capital's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 229,253 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.